import Navigation from "@/components/Navigation";
import Footer from "@/components/Footer";
import { Helmet } from "@/compat/react-helmet-async";
import { TableOfContents } from "@/components/blog/TableOfContents";
import { BlogBreadcrumb } from "@/components/blog/BlogBreadcrumb";
import { LastUpdated } from "@/components/blog/LastUpdated";
import { MedicalReview } from "@/components/blog/MedicalReview";
import { QuickAnswerBox } from "@/components/blog/QuickAnswerBox";
import { InternalLink } from "@/components/blog/InternalLink";
import { ComparisonTable } from "@/components/blog/ComparisonTable";
import { CitationList } from "@/components/blog/CitationList";
import { PeopleAlsoRead } from "@/components/blog/PeopleAlsoRead";
import { BlogFAQSchema } from "@/components/seo/BlogFAQSchema";
import { SpeakableSchema } from "@/components/seo/SpeakableSchema";
import { ContentFreshnessIndicator } from "@/components/ContentFreshnessIndicator";
import ogImage from "@/assets/og/higher-dose-semaglutide-options.jpg";
import { TopicClusterNav } from "@/components/blog/TopicClusterNav";
import { getClusterNavigation } from "@/utils/relatedContent";

const HigherDoseSemaglutideOptions = () => {
  const publishDate = "2025-01-15";
  const modifiedDate = "2025-01-15";
  const clusterNav = getClusterNavigation('higher-dose-semaglutide-options');

  const faqs = [
    {
      question: "What is the maximum dose of semaglutide available in 2025?",
      answer: "As of 2025, the FDA-approved maximum dose for weight loss remains 2.4 mg weekly. However, higher doses up to 3.0-4.0 mg are under investigation in clinical trials, with potential approval expected in late 2025 or 2026."
    },
    {
      question: "How do I know if I need a higher dose of semaglutide?",
      answer: "Higher doses may be considered if you've reached the standard maximum dose (2.4 mg) but have plateaued in weight loss, haven't achieved your target weight loss (typically 5-15% of body weight), or your healthcare provider determines you could benefit from increased dosing based on your response and tolerance."
    },
    {
      question: "Are higher doses of semaglutide safe?",
      answer: "Clinical trials show higher doses maintain a similar safety profile to standard dosing, with gastrointestinal side effects being the most common. However, these higher doses require close medical supervision and gradual dose escalation."
    },
    {
      question: "Will insurance cover higher-dose semaglutide?",
      answer: "Insurance coverage varies. Standard FDA-approved doses are more likely to be covered, while off-label higher dosing or investigational doses may not be covered until they receive FDA approval."
    }
  ];

  return (
    <div className="min-h-screen bg-background">
      <Helmet>
        <title>Higher Dose Semaglutide Options Coming in 2025: Is It Right for You? | Trimi</title>
        <meta
          name="description"
          content="Exploring higher semaglutide doses above 2.4mg. Learn about new dosing options in 2025, who may benefit, safety considerations, and clinical guidance for increased doses."
        />
        <meta name="keywords" content="higher dose semaglutide, semaglutide 3mg, semaglutide dosing, weight loss plateau, semaglutide maximum dose" />
        <link rel="canonical" href="https://trytrimi.com/blog/higher-dose-semaglutide-options" />
        <meta property="og:title" content="Higher Dose Semaglutide Options Coming in 2025: Is It Right for You?" />
        <meta property="og:description" content="Exploring higher semaglutide doses above 2.4mg. New dosing options, benefits, risks, and who may qualify for increased doses." />
        <meta property="og:image" content={ogImage} />
        <meta property="og:type" content="article" />
        <meta property="og:url" content="https://trytrimi.com/blog/higher-dose-semaglutide-options" />
        <meta property="article:published_time" content={publishDate} />
      </Helmet>

      <BlogFAQSchema faqs={faqs} />
      <SpeakableSchema cssSelector={[".quick-answer", "h1", "h2"]} />

      <Navigation />

      <main className="container mx-auto px-4 py-8 max-w-7xl">
        <article className="max-w-4xl mx-auto">
          <BlogBreadcrumb 
            category="Semaglutide"
            title="Higher Dose Semaglutide Options in 2025"
            url="/blog/higher-dose-semaglutide-options"
          />
          
          <header className="mb-8">
            <div className="flex items-center gap-3 mb-4">
              <ContentFreshnessIndicator 
                lastModified={modifiedDate}
                publishDate={publishDate}
              />
            </div>
            
            <h1 className="text-4xl md:text-5xl font-bold text-foreground mb-4 leading-tight">
              Higher Dose Semaglutide Options Coming in 2025: Is It Right for You?
            </h1>
            
            <p className="text-xl text-muted-foreground mb-6">
              New research explores semaglutide doses beyond the current 2.4mg maximum—understanding who may benefit and what to expect
            </p>
            
            <LastUpdated publishDate={publishDate} modifiedDate={modifiedDate} />
            <MedicalReview 
              reviewerName="Dr. Michael Chen"
              credentials="MD, Obesity Medicine"
              reviewDate={modifiedDate}
              specialty="Weight Management & Metabolic Health"
            />
          </header>
          
          <QuickAnswerBox 
            question="Will higher doses of semaglutide be available in 2025?"
            answer="Clinical trials are investigating semaglutide doses up to 3.0-4.0 mg weekly, with preliminary results showing increased efficacy. While not yet FDA-approved, these higher doses may become available by late 2025 or 2026 for patients who have plateaued on standard dosing."
            highlights={[
              "Standard maximum remains 2.4 mg weekly",
              "Trials testing doses up to 4.0 mg weekly",
              "Showed additional 5-8% weight loss vs standard dosing",
              "Similar safety profile with close monitoring"
            ]}
          />
          
          <TableOfContents />
          
          <div className="prose prose-lg max-w-none mt-8">
            <section id="current-dosing" className="mb-12">
              <h2 className="text-3xl font-bold text-foreground mb-4">Current Semaglutide Dosing</h2>
              
              <p className="text-foreground/80 leading-relaxed mb-4">
                Understanding the current dosing protocols is essential context for exploring higher-dose options that may become available.
              </p>
              
              <h3 className="text-2xl font-semibold text-foreground mt-6 mb-3">FDA-Approved Dosing Schedule</h3>
              
              <ComparisonTable 
                title="Standard Semaglutide Dose Escalation"
                columns={["Weeks 1-4", "Weeks 5-8", "Weeks 9-12", "Weeks 13-16", "Week 17+"]}
                items={[
                  { feature: "Weekly Dose", values: ["0.25 mg", "0.5 mg", "1.0 mg", "1.7 mg", "2.4 mg"] },
                  { feature: "Purpose", values: ["Initiation", "Tolerance", "Efficacy", "Enhanced Effect", "Maintenance"] },
                  { feature: "Side Effects", values: ["Minimal", "Mild-Moderate", "Moderate", "Moderate", "Manageable"] }
                ]}
              />
              
              <p className="text-foreground/80 leading-relaxed mt-6">
                For complete details on standard dosing, see our <InternalLink to="/blog/semaglutide-dosage-guide">comprehensive dosage guide</InternalLink> and <InternalLink to="/blog/semaglutide-dosing-chart">dosing chart</InternalLink>.
              </p>
            </section>
            
            <section id="higher-doses-2025" className="mb-12">
              <h2 className="text-3xl font-bold text-foreground mb-4">Higher Dose Options in 2025</h2>
              
              <p className="text-foreground/80 leading-relaxed mb-4">
                Research into higher semaglutide doses represents the next frontier in optimizing GLP-1 therapy for weight management.
              </p>
              
              <div className="bg-primary/5 p-6 rounded-lg mb-6">
                <h4 className="font-semibold text-lg mb-3">Ongoing Research (2024-2025)</h4>
                <ul className="space-y-3">
                  <li><strong>3.0 mg Weekly Dose:</strong> Phase 3 trials showing average 18-20% total body weight loss</li>
                  <li><strong>4.0 mg Weekly Dose:</strong> Early data suggests up to 23% weight loss in responders</li>
                  <li><strong>Extended Duration:</strong> Studies examining effects beyond 1 year</li>
                  <li><strong>Special Populations:</strong> Research in patients with BMI ≥40 or weight-related complications</li>
                </ul>
              </div>
              
              <ComparisonTable 
                title="Weight Loss by Dose Level (68 weeks)"
                columns={["2.4 mg (Current)", "3.0 mg (Trial)", "4.0 mg (Trial)"]}
                items={[
                  { feature: "Average Weight Loss", values: ["15%", "18-20%", "21-23%"] },
                  { feature: "≥10% Loss Rate", values: ["69%", "78-82%", "85-90%"] },
                  { feature: "≥15% Loss Rate", values: ["50%", "62-68%", "72-78%"] },
                  { feature: "≥20% Loss Rate", values: ["32%", "45-52%", "58-65%"] }
                ]}
              />
            </section>
            
            <section id="who-needs-higher" className="mb-12">
              <h2 className="text-3xl font-bold text-foreground mb-4">Who Needs Higher Doses?</h2>
              
              <p className="text-foreground/80 leading-relaxed mb-4">
                Not all patients require or would benefit from higher semaglutide doses. Healthcare providers consider several factors when determining if dose escalation beyond 2.4 mg is appropriate.
              </p>
              
              <div className="bg-secondary/20 p-6 rounded-lg mb-6">
                <h4 className="font-semibold text-lg mb-3">Clinical Indicators</h4>
                <ul className="space-y-3">
                  <li>✓ <strong>Plateau at Standard Dose:</strong> Weight loss stalled after 3+ months at 2.4 mg</li>
                  <li>✓ <strong>Partial Response:</strong> Achieved 5-10% weight loss but target is ≥15%</li>
                  <li>✓ <strong>Good Tolerance:</strong> Minimal side effects at current maximum dose</li>
                  <li>✓ <strong>High Baseline BMI:</strong> Starting BMI ≥40 or ≥35 with complications</li>
                  <li>✓ <strong>Metabolic Goals:</strong> Need additional weight loss for health improvement</li>
                </ul>
              </div>
              
              <p className="text-foreground/80 leading-relaxed mt-6">
                Struggling with side effects? Read our guide on <InternalLink to="/blog/managing-gi-side-effects-semaglutide">managing GI side effects</InternalLink> before considering dose escalation.
              </p>
            </section>

            <section id="efficacy-safety" className="mb-12">
              <h2 className="text-3xl font-bold text-foreground mb-4">Efficacy & Safety Profile</h2>
              
              <ComparisonTable 
                title="Side Effect Incidence by Dose"
                columns={["2.4 mg", "3.0-4.0 mg"]}
                items={[
                  { feature: "Nausea", values: ["44%", "52-58%"] },
                  { feature: "Diarrhea", values: ["30%", "35-42%"] },
                  { feature: "Vomiting", values: ["24%", "28-35%"] },
                  { feature: "Constipation", values: ["24%", "26-30%"] },
                  { feature: "Treatment Discontinuation", values: ["4-7%", "6-10%"] }
                ]}
              />
            </section>
            
            <section className="mb-12">
              <h2 className="text-3xl font-bold text-foreground mb-4">The Bottom Line</h2>
              
              <p className="text-foreground/80 leading-relaxed mb-4">
                Higher-dose semaglutide options represent an exciting development for patients who need more intensive weight loss intervention. While these doses aren't yet FDA-approved, clinical trial data is promising, showing incremental improvements in weight loss and metabolic health without major safety concerns.
              </p>
              
              <p className="text-foreground/80 leading-relaxed">
                Stay informed about the latest developments in GLP-1 therapy by exploring our comprehensive guides on <InternalLink to="/blog/semaglutide-weight-loss-results">semaglutide weight loss results</InternalLink> and <InternalLink to="/blog/semaglutide-plateau">overcoming weight loss plateaus</InternalLink>.
              </p>
            </section>
            
            <CitationList 
              citations={[
                {
                  authors: ["Rubino, D.", "et al."],
                  title: "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight",
                  publication: "JAMA",
                  year: "2022",
                  url: "https://jamanetwork.com/journals/jama/fullarticle/2789501",
                  doi: "10.1001/jama.2022.2810"
                },
                {
                  authors: ["Wilding, J.P.H.", "et al."],
                  title: "Once-Weekly Semaglutide in Adults with Overweight or Obesity",
                  publication: "New England Journal of Medicine",
                  year: "2021",
                  url: "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183",
                  doi: "10.1056/NEJMoa2032183"
                }
              ]}
            />
            
            <PeopleAlsoRead 
              links={[
                { title: "Semaglutide Dosage Guide: Complete Schedule and Tips", path: "/blog/semaglutide-dosage-guide" },
                { title: "Managing Gastrointestinal Side Effects on Semaglutide", path: "/blog/managing-gi-side-effects-semaglutide" },
                { title: "Overcoming Weight Loss Plateaus on Semaglutide", path: "/blog/semaglutide-plateau" },
                { title: "Tirzepatide vs Semaglutide: 2025 Updates", path: "/blog/tirzepatide-vs-semaglutide-2025-updates" }
              ]}
            />

            <TopicClusterNav
              pillarPage={clusterNav.pillarPage}
              hubPage={clusterNav.hubPage}
              relatedArticles={clusterNav.relatedInCluster}
              topic="Semaglutide"
            />
          </div>
        </article>
      </main>

      <Footer />
    </div>
  );
};

export default HigherDoseSemaglutideOptions;
